Rosie Bradbury

Small modular reactors, which can be combined for a single project and scaled easily, are some VCs' latest obsession.

The SEC is reportedly preparing a proposal, but it's unlikely to move the needle amid seemingly unlimited private capital.

EMed has raised $200 million at a $2 billion valuation. But will its GLP-1 adherence rate hold up at scale?

New injectable peptides could take on a similar trajectory to GLP-1 drugs—but they'd come with risks.

Anthropic says its new model has identified threats that decades of cyber researchers have failed to detect. Will some startups' moats disintegrate?

Hawkeye 360 filed its S-1 on Friday with little fanfare, but it'll be an early signal about investor appetite.

Funds like the highly popular QQQ that track the Nasdaq 100 will be compelled to buy a lot of SpaceX shares very quickly.

VCs are investing more in the technology in service of a grand vision of a digital, eternal life. But user acquisition is still a big hurdle.

The gap between AI spending and productivity gains "should be making executives uncomfortable," a Bain report found.

Alongside the athletes, both Whoop and Oura are competing at the crown jewel of soccer tournaments